Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up

Urologic Oncology: Seminars and Original Investigations

Volumn 23, Issue 1, 2005, Pages 1-7

  Berruti, Alfredo ^a   Fara, Enrica ^a   Tucci, Marcello ^a   Tarabuzzi, Roberto ^b   Mosca, Alessandra ^a   Terrone, Carlo ^b   Gorzegno, Gabriella ^a   Fasolis, Giuseppe ^c   Tampellini, Marco ^a   Porpiglia, Francesco ^b   De Stefanis, Marinella ^d   Fontana, Dario ^e   Bertetto, Oscar ^f   Dogliotti, Luigi ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c San Lazzaro Hospital   (Italy)

^d Ospedale San Lazzaro   (Italy)

^e Urologia Azienda Ospedaliera M   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Hormone refractory disease; Long term follow up; Phase II study; Prostate cancer

Indexed keywords

ESTRAMUSTINE PHOSPHATE; ETOPOSIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EDEMA; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEART INFARCTION; HUMAN; INFECTION; LUNG EMBOLISM; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; ETOPOSIDE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 21044432367     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.06.003     Document Type: Article

References (30)

1. R. De Angelis, R. Capocaccia, A. Verdecchia Estimative relative survival of Italian cancer patients from sparse cancer registries data Tumori 83 1997 33 38
2. S. Goodin, K.V. Rao, R.S. Di Paola State-of-the art treatment of metastatic hormone-refractory prostate cancer patients Oncologist 7 2002 360 370
3. S. Culine, J.P. Droz Chemotherapy in advanced androgen-independent prostate cancer 1990-1999 a decade of progress? Ann Oncol 11 2002 1523 1530
4. H.I. Scher, M. Mazumbdar, W.K. Kelly Clinical trials in relapsed prostate cancer defining the target J Natl Cancer Inst 88 1996 1623 1634
5. W.K. Oh Chemotherapy for patients with advanced prostate carcinoma. A new option for therapy Cancer 88 suppl. 12 2000 3015 3021
6. G.J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, M. Eisenberger Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the prostate-specific antigen working group J Clin Oncol 17 1999 3461 3467
7. W.R. Parulekar, E.A. Eisenhauer Novel end-points and design of early clinical trials Ann Oncol 13 suppl. 4 2002 139 143
8. H. Scher, G. Heller Picking the winner in a sea of plenty Clin Cancer Res 8 2002 400 404
9. G.L. Wang, X.M. Liu, W. Kreis, D.R. Budman The effect of antimicrotubule agents on signal transduction pathways of apoptosis a review Cancer Chemother Pharmacol 44 1999 351 361
10. K.J. Pienta, B. Redman, M. Hussain Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate J Clin Oncol 12 1994 2005 2012
11. D.C. Smith, P. Esper, M. Strawderman, B. Redman, K.J. Pienta Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer J Clin Oncol 17 1999 1664 1671
12. M. Colleoni, C. Graiff, G. Vicario Phase II study of estramustine, oral etoposide, and vinorelbine in hormone refractory prostate cancer Am J Clin Oncol (CCT) 20 1997 383 386
13. A.B. Miller, B. Hoogstroten, M. Staquet, A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
14. R.E. Coleman Evaluation of bone disease in breast cancer Breast 3 1993 73 78
15. R. Simon Optimal two-stage design for phase II clinical trials Control Clin Trials 10 1989 1 10
16. K.J. Pienta, B.G. Redman, R. Bandekar A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer Urology 50 1997 401 407
17. K.J. Pienta, E.I. Fisher, M. Eisenberger A phase II trial of estramustine and etoposide in hormone refractory prostate cancer a Southwest Oncology Group Trial (SWOG 9407) Prostate 46 2001 257 261
18. Y. Sumiyoshi, K. Hashine, H. Nakatsuzi, Y. Yamashita, T. Karashima Oral estramustine and oral etoposide for the treatment of hormone refractory prostate cancer Int J Urol 7 2000 243 247
19. M.A. Dimopoulos, C. Panopoulos, C. Bamia Oral estramustine and oral etoposide for hormone-refractory prostate cancer Urology 50 1997 754 758
20. H.G. Munshi, K.J. Pienta, D.C. Smith Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma. A phase II trial of oral estramustine and oral etoposide Cancer 91 2001 2175 2180
21. G. Hudes, L. Einhorn, E. Ross Vinblastine versus vinblastin plus oral estramustine phosphate for patients with hormone refractory prostate cancer a Hoosier Oncology Group and Fox Chase Network phase III trial J Clin Oncol 17 1999 3160 3166
22. S. Urakami, M. Igawa, N. Kikuno Combination chemotherapy with paclitaxel, estramustine and cisplatin for hormone refractory prostate cancer J Urol 168 2002 2444 2450
23. D.M. Savarese, S. Halabi, V. Hars Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer a final report of CALGB 9780 J Clin Oncol 19 2001 2509 2516
24. V.J. Sinibaldi, M.A. Carducci, S. Moore-Cooper, M. Laufer, M. Zahurak, M.A. Eisenberger Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 2002 1457 1465
25. I.F. Tannock, D. Osoba, M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer a Canadian randomised trial with palliative end points J Clin Oncol 14 1996 1756 1764
26. A. Berruti, L. Dogliotti, A. Mosca Circulating neuroendocrine markers in patients with prostate carcinoma Cancer 88 2000 2590 2597
27. P. Di Sant'Agnese, A.T. Cockett Neuroendocrine differentiation in prostatic malignancy Cancer 78 1996 357 361
28. W.K. Kelly, T. Curley, S. Slavin Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer J Clin Oncol 19 2001 44 53
29. T. Gilligan, P.W. Kantoff Chemotherapy for prostate cancer Urology 60 2002 94 100
30. U. Vaishampayan, J. Fontana, M. Hussain An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer Urology 60 2002 1050 1054